EML4 and non-small cell lung carcinoma: In the current research, as cohort studies indicated a heightened risk of VTE occurrence in patients with ALK-rearranged NSCLC [4, 6], we targeted inhibition of EML4-ALK fusion protein in NSCLC cells and observed that TF expression was significantly decreased.